The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Tous droits réservés
ID Serval
serval:BIB_E4C54B5D3225
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders
Périodique
Mini Reviews in Medicinal Chemistry
Auteur⸱e⸱s
Juillerat-Jeanneret L., Gerber-Lemaire S.
ISSN
1389-5575
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
9
Numéro
2
Pages
215-226
Langue
anglais
Résumé
Many biologically active peptides are protected from general proteolytic degradation by evolutionary conserved prolines (Pro), due to conformational constraints imposed by the Pro residue. Thus the biological importance of prolyl-specific peptidases points to a high potential for drug discovery for this family of enzymes. Panels of inhibitors have been synthesized and their effects, determined in biological models, suggest the inhibition of families of enzymes with similar activities. Prolyl-specific aminodipeptidases include dipeptidyl-aminodipeptidase IV (DPP IV)/CD26, DPP8, DPP9 and fibroblast activation protease-alpha (FAP-alpha)/seprase, able to release X-Pro dipeptides from the N-terminus of peptides. DPP IV inhibitors are in clinical use for type 2 diabetes. In this review, the expression and the potential functions of prolyl-aminodipeptidases are reviewed in diseases, and the inhibitors developed for these enzymes are discussed, with a specific focus on inhibitors able to discriminate between DPP IV and fibroblast activation protease-alpha (FAPalpha)/seprase as potential leads for the treatment of fibrogenic diseases.
Mots-clé
Aminopeptidases, Animals, Antigens, Neoplasm, Dipeptidyl-Peptidase IV Inhibitors, Enzyme Inhibitors, Fibrosis, Humans, Serine Endopeptidases, Tumor Markers, Biological
Pubmed
Web of science
Création de la notice
20/05/2009 18:31
Dernière modification de la notice
11/06/2020 5:21
Données d'usage